Chiron Licenses Acute Rejection Agent From Novartis

Chiron has acquired exclusive worldwide development and commercialization rights to aerosolized cyclosporine (AcsA), an agent with potential in lung transplant acute rejection from Novartis. Clinical studies have been conducted in about 100 lung transplant patients at the University of Pittsburgh. Terms of agreement were not disclosed. Chiron Corporation, headquartered in Emeryville, California, has a strategic Read more about Chiron Licenses Acute Rejection Agent From Novartis[…]

Philips, Dow And Kereos To Collaborate With Washington University

Royal Philips Electronics, Dow Chemical Company and Kereos, Inc. are to collaborate in a $2.8 million, 3-year contract awarded by the National Cancer Institute (NCI) to Barnes Jewish Hospital (BJH) and Washington University School of Medicine in St. Louis. The collaborators will develop and test novel molecular imaging agents for early non-invasive detection of certain Read more about Philips, Dow And Kereos To Collaborate With Washington University[…]

Axonyx Announces Milestone Payment From Serono

Under the terms of a license agreement for beta-sheet breaker technology, Axonyx Inc. has announced the receipt of a milestone payment of $1 million from Serono S.A. The milestone payment was triggered when Serono initiated a Phase I clinical trial with a beta-sheet breaker peptide for the potential treatment of Alzheimer’s disease. The study will Read more about Axonyx Announces Milestone Payment From Serono[…]